13 recruiting, 7 unknown, 6 not yet recruiting, 1 completed. 10 Phase 2, 5 Not applicable, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Unknown 4, Not yet recruiting 2 |
| Not applicable | 5 | Recruiting 3, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Upper Tract Urothelial Carcinoma: new trials by email Literature Review of Upper Tract Urothelial Carcinoma trials Research Report on Upper Tract Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC) Signatera testing - Upper Tract Urothelial Carcinoma | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2026-12-01 | 2026-10-29 | |
| Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA 5-Aminolevulinic acid Hydrochloride (Gliolan®) - Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Henry Ford Health System | 10 | 2026-09-15 | 2026-09-18 |
| OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma OptiCross HD Coronary Imaging Catheter - Upper Tract Urothelial Carcinoma | Not applicable | Not yet recruiting | Yonsei University | 15 | 2026-09-01 | 2026-08-07 |
| Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma RC48 Combined With Tislelizumab - Upper Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | RenJi Hospital | 50 | 2026-05-31 | 2026-05-13 |
| Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2) - Upper Tract Urothelial Carcinoma | Phase 3 | Recruiting | Peking University First Hospital | 192 | 2026-05-01 | 2026-09-28 |
| Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma | Recruiting | Ruijin Hospital | 477 | 2026-04-05 | 2026-10-22 | |
| Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma SBRT - Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy, Upper Tract Urothelial Carcinoma | Not yet recruiting | Peking University First Hospital | 36 | 2026-04-01 | 2026-04-24 | |
| Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma EB-DT-NK-UC101, Cyclophosphamide, Fludarabine - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-03-25 |
| NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection - Upper Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | Peking University Third Hospital | 40 | 2026-02-01 | 2026-02-17 |
| Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma | Recruiting | AZ Sint-Lucas Gent | 70 | 2025-11-07 | 2026-08-10 | |
| Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma Flexible ureterorenoscopy - Upper Tract Urothelial Carcinoma | Not applicable | Recruiting | Chinese University of Hong Kong | 10 | 2025-10-01 | 2026-10-27 |
| Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC) - Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Samsung Medical Center | 48 | 2025-09-16 | 2025-11-06 |
| Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC) Template Lymph Node Dissection, Selective Lymph Node Resection - Upper Tract Urothelial Carcinoma, Lymph Node Dissection | Not applicable | Recruiting | Tianjin Medical University Second Hospital | 150 | 2025-09-01 | 2026-06-25 |
| Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU) - Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-17 |
| Ambulatory Flexible URS for UTUC Surveillance Ambulatory flexible ureterorenoscopy - Upper Tract Urothelial Carcinoma | Phase 1 | Recruiting | Chinese University of Hong Kong | 10 | 2025-07-01 | 2025-09-15 |
| HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study Chemotherapy, Immunotherapy, ADC - Upper Tract Urothelial Carcinoma | Not yet recruiting | Peking University First Hospital | 200 | 2025-02-01 | 2025-01-29 | |
| A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial Best Practice, Exercise Intervention, App-Based Intervention - Bladder Cancer, Urothelial Carcinoma | Not applicable | Recruiting | University of Washington | 128 | 2023-12-19 | 2026-09-10 |
| A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma RC48-ADC and JS001 - Carcinoma, Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Jinling Hospital, China | 30 | 2022-11-23 | 2025-01-22 |
| Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection Active Comparator: Surgery Pathology or Cystoscopy, Active Comparator: Clinical Diagnosis - Upper Tract Urothelial Carcinoma | Unknown | AnchorDx Medical Co., Ltd. | 490 | 2020-09-01 | 2023-05-24 | |
| Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma | Recruiting | Henan Provincial People's Hospital | 800 | 2019-10-08 | 2026-07-02 |
Showing 20 of 27. Sign in to see all of them.
Carcinoma, Transitional Cell (5) · Urinary Bladder Neoplasms (4) · Carcinoma (1) · Disease (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Pathologic Complete Response (1) · Recurrence (1)
Neoplasms (8) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Urinary Bladder Diseases (4)
pirarubicin (3) · Gemcitabine (2) · Lymph Node Excision (2) · tislelizumab (2) · 130-nm albumin-bound paclitaxel (1) · Aminolevulinic Acid (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Cystoscopy (1) · Drug Therapy (1) · Endoscopy (1) · Epirubicin (1) · Exercise Test (1) · Immunotherapy (1)
Peking University First Hospital (6) · Chinese University of Hong Kong (2) · RenJi Hospital (2) · Tianjin Medical University Second Hospital (2) · AZ Sint-Lucas Gent (1) · AnchorDx Medical Co., Ltd. (1) · Beijing Biotech (1) · Henan Provincial People's Hospital (1) · Henry Ford Health System (1) · Jinling Hospital, China (1) · Memorial Sloan Kettering Cancer Center (1) · Peking University Third Hospital (1) · Ruijin Hospital (1) · Samsung Medical Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
China (15) · United States (4) · Hong Kong (2) · Belgium (1) · Netherlands (1) · Norway (1) · South Korea (1) · Spain (1)
Changyi Quan, MD (1) · Hailong Hu, PhD (1) · Jeannie Hoffman-Censits, MD (1) · Johar Raza, MD (1) · Jonathan Coleman, MD (1) · Liqun Zhou, M.D. (1) · Sarah Psutka (1) · Susanne Osanto, MD, PhD (1) · Wei Xue, M.D (1) · Zhifeng Wang, PhD (1)